Table 4.
Baseline Characteristics and Post Transplant Outcomes Stratified by Rejection
| 144 total patients | No Rejection (n=81) N (%) or mean± SD |
Rejection (n=63) N (%) or mean± SD |
p Value |
|---|---|---|---|
| Age | 52.4±11.6 | 55.8±10.2 | p = ns |
| Gender | |||
| Male (%) | 54 (67) | 42 (67) | p = ns |
| Female (%) | 27 (33) | 21 (33) | p = ns |
| MELD | 21.4±10.2 | 19.7±9.3 | p = ns |
| Etiology | p = ns | ||
| HCV (%) | 25 (31) | 31 (49) | |
| Alcoholic (%) | 14 (17) | 8 (13) | |
| PSC (%) | 11 (14) | 9 (14) | |
| HBV (%) | 8 (10) | 5 (8) | |
| Other cause (%) | 23 (28) | 10 (16) | |
| Type of transplant | |||
| Liver (%) | 59 (73) | 54 (86) | p = ns |
| Liver-Kidney (%) | 22 (27) | 9 (14) | p = ns |
| Pre-transplant Diabetes | 22 (27%) | 28 (44%) | p = 0.0354 |
| Average Glucose Pre-Transplant |
129.1±43.9 | 146.0±45.0 | p = ns |
| Average Glucose Post-Transplant |
159.2±31.8 | 186.5±41.4 | p = ns |
| Average # of Infections | 1.19 | 1.89 | p<0.001 |
| Average Rehospitalization Days |
5.75 | 11.12 | p<0.001 |
| Average Prednisone Dose | 179.9 ± 156.8 | 215.6 ± 130.1 | p=ns |
| Proportions using Tacrolimus |
92.6% | 100% | p=ns |
| Tacrolimus Average Levels (ng/mL) |
8.16 ± 3.73 | 9.42 ± 4.65 | p=ns |
MELD – Model of End-Stage Liver Disease; HCV – Hepatitis C Virus; PSC – Primary Sclerosing Cholangitis; HBV – Hepatitis B Virus